Febuxostat: all 69 studies that test it
Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.
- Clinical Study to Evaluate the Efficacy of Febuxostat in the Treatment of Conservatively Managed Intracranial Hemorrhage PatientsRecruitingNCT07701512Phase 2
- Boosting Osimertinib Blood Brain Barrier PenetrationRecruitingNCT07485452Phase 2
- HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-EffectivenessNot yet recruitingNCT07369622Phase 4
- The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and HyperuricemiaRecruitingNCT07362355Phase 2
- Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy SubjectsNot yet recruitingNCT07181265Phase 1
- A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's DiseaseRecruitingNCT07170475Phase 1
- Clinical Study to Evaluate the Possible Efficacy and Safety of Febuxostat in Patients With Ulcerative Colitis Treated With MesalamineNot yet recruitingNCT06525974Early Phase 1
- Immediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed AdministrationRecruitingNCT05109936Phase 3
- Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and AdultsTerminatedNCT03605212Phase 1/2Results posted
- Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine ExcretionCompletedNCT02752633Phase 4Results posted
- Phase 1, Febuxostat XR Relative Bioavailability StudyCompletedNCT02504320Phase 1Results posted
- Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With GoutCompletedNCT02500641Phase 4Results posted
- Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release CapsuleCompletedNCT02382640Phase 1Results posted
- Food Effect Study of Febuxostat XR in Healthy ParticipantsCompletedNCT02374164Phase 1Results posted
- Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With GoutCompletedNCT02139046Phase 3Results posted
- Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal ImpairmentCompletedNCT02128490Phase 2Results posted
- Safety and Efficacy of Oral Febuxostat in Subjects With GoutCompletedNCT02082769Phase 3Results posted
- Lesinurad and Febuxostat Combination Extension Study in GoutCompletedNCT01808144Phase 3Results posted
- The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable AnginaCompletedNCT01763996Phase 4Results posted
- Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic MalignanciesCompletedNCT01724528Phase 3Results posted
- The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot StudyTerminatedNCT01701622Not applicableResults posted
- Effects of Hyperuricemia Reversal on Features of the Metabolic SyndromeCompletedNCT01654276Phase 4Results posted
- Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable AnginaTerminatedNCT01549977Phase 2Results posted
- Effect of Febuxostat on Blood PressureCompletedNCT01496469Phase 2Results posted
- Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood PressureCompletedNCT01472692Phase 4Results posted
- Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney DiseaseCompletedNCT01350388Not applicableResults posted
- Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)CompletedNCT01328769Phase 4Results posted
- An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.CompletedNCT01112982Phase 4Results posted
- Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)CompletedNCT01101035Phase 3Results posted
- Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal ImpairmentCompletedNCT01082640Phase 2Results posted
- Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early GoutCompletedNCT01078389Phase 2Results posted
- Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate StonesCompletedNCT01077284Phase 2Results posted
- Efficacy and Safety of Oral Febuxostat in Participants With GoutCompletedNCT00430248Phase 3Results posted
- Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010CompletedNCT00175019Phase 3Results posted
- Dose-Response, Safety and Efficacy of Febuxostat in Subjects With GoutCompletedNCT00174967Phase 2Results posted
- Long-Term Safety of Febuxostat in Subjects With Gout.CompletedNCT00174941Phase 2Results posted
- Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.CompletedNCT00174915Phase 3Results posted
- Febuxostat Versus Allopurinol Control Trial in Subjects With GoutCompletedNCT00102440Phase 3Results posted
- Comparison of the Effect of Allopurinol Versus Febuxostat on Serum Uric Acid in Patients With Chronic Kidney Disease Associated With HyperuricemiaActive, not recruitingNCT07850713Not applicable
- Febuxostat Effect on Chronic Kidney Disease Progression And Carotid Intima-Media ThicknessCompletedNCT06997952Phase 1
- A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout PatientsCompletedNCT05815901Phase 3
- A Drug-drug Interaction Study to Evaluate the Effect of Rifampicin and Febuxostat on the Pharmacokinetics of Methotrexate in Healthy SubjectsCompletedNCT05575297Phase 1
- Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients with HyperuricemiaActive, not recruitingNCT05574036Phase 2
- Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD PatientsCompletedNCT05474560Phase 4
- Renoprotective Effect of Febuxostat on Contrast Induced Acute Kidney Injury in Chronic Kidney Disease Patients Stage 3CompletedNCT05264584Not applicable
- A Randomized Clinical Trail of The Effect of Postoperative Uric Acid Control on Stone Recurrence and Renal Function in Patients With Hyperuricemia of Urolithiasis.Status unknownNCT04398251Phase 4
- Bioequivalence Study of Two Formulations of Febuxostat 120 mg Film-coated Tablets in Healthy Adult Volunteers After a Single Oral Dose Administration Under Fasting ConditionsCompletedNCT03918551Phase 1
- Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)Status unknownNCT03767322Phase 2
- Urate Lowering Therapies and Left Ventricular Diastolic DysfunctionStatus unknownNCT03534037Phase 4
- Effect of Hyperuricaemia on Chronic Renal DiseaseStatus unknownNCT03425708Phase 4
- Uric Acid Effects on Endothelium and Oxydative StressCompletedNCT03395977Not applicable
- The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF)Status unknownNCT03336203Phase 4
- Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis PatientsStatus unknownNCT03200210Phase 4
- The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With GoutCompletedNCT03131583Phase 1
- Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese PatientsStatus unknownNCT02944214Not applicable
- Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.CompletedNCT02866214Phase 2/3
- Zurig (Febuxostat) 40mg Efficacy and Safety TrialCompletedNCT02600780Phase 4
- The Effect of Uric Acid Lowering in Type 1 DiabetesCompletedNCT02344602Phase 4
- Compare the Renal Protective Effects of Febuxostat and BenzbromaroneCompletedNCT02338323Not applicable
- A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia PatientsCompletedNCT02317861Phase 1/2
- the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and HyperuricemiaTerminatedNCT02279342Phase 4
- Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With GoutCompletedNCT02252835Phase 2
- Febuxostat for Cerebral and caRdiorenovascular Events prEvEntion stuDyStatus unknownNCT01984749Not applicable
- RDEA3170 and Febuxostat Drug Interaction StudyCompletedNCT01883167Phase 1
- A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With GoutCompletedNCT01736514Phase 3
- Clinical Study to Evaluate the Pharmacokinetic Characteristics Between TMX-67 and Feburic® in Healthy VolunteersCompletedNCT01563432Phase 1
- Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout PatientsCompletedNCT01416402Phase 2
- Study of Tranilast Alone or in Combination With Febuxostat in Patients With HyperuricemiaCompletedNCT00995618Phase 2
- Phase III Trial of Febuxostat in Korea Gout PatientsCompletedNCT00821392Phase 3